Isofagomine tartrate: Glycogen phosphorylase inhibitor treatment of Gaucher's disease

Drugs of the Future

Volumn 34, Issue 1, 2009, Pages 23-25

  Dulsat, C ^a   Mealy, N ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AT 2101; ENZYME INHIBITOR; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; GLYCOGEN PHOSPHORYLASE; HGT 3410; ISOFAGOMINE TARTRATE; NN 42 1007; PLICERA; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME REPLACEMENT; GAUCHER DISEASE; GENE MUTATION; HUMAN; NONHUMAN; REVIEW; SKIN FIBROBLAST;

EID: 76649093920     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.01.1323946     Document Type: Review

References (35)

1. Pandey, G., Kapur, M. A general strategy towards the synthesis of 1-N-iminosugar type glycosidase inhibitors: Demonstration by the synthesis of D-as well as L-glucose type iminosugars (isofagomines). Tetrahedron Lett 2000, 41(45): 8821-4.
2. Iida, H. et al. Total synthesis of (+)-nojirimycin and (+)-1-deoxynojirimycin. J Org Chem 1987, 52(15): 3337.
3. Feit, P.W. 1,4-Bismethanesulfonates of the stereoisomeric butanetetraols and related compounds. J Med Chem 1964, 7: 14-7.
4. Pandey, G., Kapur, M. A novel approach to both the enantiomers of potent glycosidase inhibitor isofagomine via PET-promoted cyclization of 1-[benzyl(trimethylsilylmethyl)amino]-1,4,5-trideoxy-2,3-0-(1-methylethylidene) -threo-pent-4-ynitol. Synthesis (Stuttgart) 2001, (8): 1263-7.
5. Jespersen, T.M., Bols, M., Sierks, M.R., Skrydstrup, T. Synthesis of isofagomine, a novel glycosidase inhibitor. Tetrahedron 1994, 50(47): 13449-60.
6. Lundgren, K., Kirk, O. (Novo Nordisk A/S). Piperidines and pyrrolidines. EP 0749423, JP1997509947, JP 2008056688, WO 1995024391.
7. Hansen, S.U., Bols, M. Synthesis of (±)-isofagomine and its stereoisomers from arecoline. J Chem Soc Perkin Trans I 2000, (6): 911-5.
8. Jakobsen, P., Lundbeck, J.M., Kristiansen, M. et al. Iminosugars: Potential inhibitors of liver glycogen Phosphorylase. Bioorg Med Chem 2001, 9(3): 733-44.
9. Zhao, G., Deo, U.C., Ganem, B. Selective Fowler reductions: Asymmetric total syntheses of isofagomine and other 1-azasugars from methyl nicotinate. Org Lett 2001, 3(2): 201-3.
10. Mugrace, B., Tretyakov, A., Zhu, X., Sheth, K.A., Rybczynski, P.J., Fuerst, D. (Amicus Therapeutics, Inc.). New method for preparing isofagomine and its derivatives. WO 2008144773.
11. Zhu, X., Sheth, A.K., Li, S., Chang, H.-H., Fan, J.-Q. Rational design and synthesis of highly potent beta-glucocerebrosidase inhibitors. Angew Chem lnt Ed 2005, 44(45): 7450-3.
12. Best, M.W., MacDonald, M.J., Skelton, W.B., Stick, R.V., Tilbrook,D.M.G., White, A.H. The synthesis of a carbohydrate-like dihydrooxazine and tetrahydrooxozine as putative inhibitors of glycoside hydrolases: A direct synthesis of isofagomine. Can J Chem 2002, 80: 857-65.
13. Mugrage, B., Palling, D., Sheht, K.A., Rybczynski, P.J. (Amicus Therapeutics, Inc.). Tartrate salt of isofagomine and methods of use. EP1860101, JP 2007314540, WO 2007140212.
14. Andersch, J., Bols, M. Efficient synthesis of isofagomine and noeuromycin. Chem Eur J 2001, 7(17): 3744.
15. Guanti, G., Riva, R. Asymmetrized tris(hydroxymethyl)methane as precursor of iminosugars: Application to the synthesis of isofagomine. Tetrahedron Lett 2003, 44(2): 357-60.
16. Banfi, L., Guanti, G., Paravidino, M., Riva, R. Asymmetrized tris(hydroxymethyl)methane as a precursor of N- and O-containing 6-membered heterocycles through ring-closing metathesis. Org Biomol Chem 2005, 3(9): 1729-37.
17. Ouchi, H., Mihara, Y., Takahata, H. A new route to diverse 1-azasugars from N-Boc-5-hydroxy-3-piperidine as a common buiding block. J Org Chem 2005, 70: 5207-14.
18. Ouchi, H., Mihara, Y., Watanabe, H., Takahata, H. A short and concise synthesis of isofagomine, homoisofagomine, and 5-deoxyisofagomine. Tetrahedron Lett 2004, 45(38): 7053-6.
19. Mihara, Y., Ojima, H., Imahori, T., Yoshimura, Y., Ouchi, H., Takahata, H. Asymmetric synthesis of all stereoisomers of isofagomine using (2,3)-Wittig rearrangement. Heterocycles 2007, 72(1): 633-45.
20. Imahori, T., Ojima, H., Tateyama, H., Mihara, Y., Takahata, H. Acceleration effect of allylic hydroxy group on ring-closing enyne metathesis of terminal alkynes: Scope and application to the synthesis of isofagomine. Tetrahedron Lett 2008, 49(2): 265-8.
21. Brady, R.O., Kanfer, J.N., Bradley, R.M., Shapiro, D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest 1966, 45(7): 1112-5.
22. Grabowski, G.A. Gaucher disease. Enzymology, genetics, and treatment. Adv Hum Genet 1993, 21: 377-441.
23. Sawkar, A.R., D'Haeze, W., Kelly, J.W. Therapeutic strategies to ameliorate lysosomal storage disorders - A focus on Gaucher disease. Cell Mol Life Sci 2006, 63(10): 1179-92.
24. Safety study of AT2101 in adult patients with type 1 Gaucher disease currently receiving enzyme replacement therapy (NCT00433147). ClinicalTrials.gov Web site, January 2, 2009.
25. A study to evaluate and characterize the effect of pharmacological chemicals on blood from patients with Gaucher disease (NCT00465062). ClinicalTrials.gov Web site, January 2, 2009.
26. A study of oral AT2101 in treatment-naive patients with Gaucher disease (NCT00446S50). ClinicalTrials.gov Web site, January 2, 2009.
27. A long-term extension study of AT2101 in type 1 Gaucher patients (NCT00813865). ClinicalTrials.gov Web site, January 2, 2009.
28. Steet, R.A., Chung, S., Wustman, B., Powe, A., Do, H., Kornfeld, S.A. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci USA 2006, 103(37): 13813-8.
29. Wustman, B.A., Khanna, R., Palling, D.J. et al. A new therapeutic approach to the treatment of Gaucher disease: Mechanisms of action of the pharmacological chaperone AT2101 and phase 1 trial results. 57th Annu Meet Am Soc Hum Genet (ASHG) (Oct 23-27, San Diego) 2007, Abst 2256/W.
30. Do, H., Steet, R.A., Wustman, B. et al. A new approach to the treatment of Gaucher's disease: Mechanism of enhancement of N370S GCase activity. Annu Clin Genet Meet (March 21-25, Nashville) 2007, Abst 68.
31. Steet, R., Chung, S., Lee, W.S., Pine, C.W., Do, H., Kornfeld, S. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol 2007, 73(9): 1376-83.
32. Khanna, R., Soska, R., Lun, Y. et al. The pharmacological chaperone isofagomine increases L444P GCase levels in mice with a Gaucher disease-like phenotype. Annu Clin Genet Meet (March 21-25, Nashville) 2007, Abst 67.
33. Palling, D.J., Ludwig, K., Casar, M. et al. Phase 1 studies of the safety, pharmacokinetics and pharmacodynamics of AT2101, a pharmacological chaperone or the treatment of Gaucher disease. Annu Clin Genet Meet (March 21-25, Nashville) 2007, Abst 154.
34. Pine, C.W., Ranes, B.E., Insinga, F. et al. The pharmacological chaperone AT2101 increases beta-glucocerebrosidase levels in macrophages and lymphoblasts derived from Gaucher patients. 57th Annu Meet Am Soc Hum Genet (ASHG) (Oct 23-27, San Diego) 2007, Abst 2254/W.
35. Pine, C.W., Ranes, B.E., Insinga, F. et al. A Gaucher disease ex vivo response study: The pharmacological chaperone AT2101 increases levels of glucocerebroside in patient-derived cells. 39th Eur Hum Genet Conf (June 16-19, Nice) 2007, Abst P1406.